|
1
|
Malvezzi M, Bertuccio P, Levi F, La
Vecchia C and Negri E: European cancer mortality predictions for
the year 2013. Ann Oncol. 24:792–800. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanks GE, Coia LR and Curry J: Patterns of
care studies: past, present, and future. Semin Radiat Oncol.
7:97–100. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Owen JB, Sedransk J and Pajak TF: National
averages for process and outcome in radiation oncology: methodology
of the patterns of care study. Semin Radiat Oncol. 7:101–107. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boeck S, Bruns CJ, Sargent M, Schäfer C,
Seufferlein T, Jauch KW and Heinemann V: Current oncological
treatment of patients with pancreatic cancer in Germany: results
from a national survey on behalf of the Arbeitsgemeinschaft
Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft
Onkologie of the Germany Cancer Society. Oncology. 77:40–48. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kato H, Usui M, Isaji S, Nagakawa T, Wada
K, Unno M, Nakao A, Miyakawa S and Ohta T: Clinical features and
treatment outcome of borderline resectable pancreatic head/body
cancer: a multi-institutional survey by the Japanese Society of
Pancreatic Surgery. J Hepatobiliary Pancreat Sci. Mar 14–2013.Epub
ahead of print. View Article : Google Scholar
|
|
6
|
Ogawa K, Ito Y, Karasawa K, Ogawa Y,
Onishi H, Kazumoto T, Shibuya K, Shibuya H, Okuno Y, Nishino S, Ogo
E, Uchida N, Karasawa K, Nemoto K and Nishimura Y: JROSG Working
Subgroup of Gastrointestinal Cancers: Patterns of radiotherapy
practice for pancreatic cancer in Japan: results of the Japanese
Radiation Oncology Study Group (JROSG) survey. Int J Radiat Oncol
Biol Phys. 77:743–750. 2010. View Article : Google Scholar
|
|
7
|
Wang Y, Schrag D, Brooks GA and Dominici
F: National trends in pancreatic cancer outcomes and pattern of
care among Medicare beneficiaries, 2000 through 2010. Cancer.
120:1050–1058. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramella S, Maranzano E, Frata P, Mantovani
C, Lazzari G, Menichelli C, Navarria P, Pergolizzi S and Salvi F:
Radiotherapy in Italy for non-small cell lung cancer: patterns of
care survey. Tumori. 98:66–78. 2012.PubMed/NCBI
|
|
9
|
Aristei C, Amichetti M, Ciocca M, Nardone
L, Bertoni F and Vidali C; Italian Society of Radiation Oncology:
Radiotherapy in Italy after conservative treatment of early breast
cancer. A survey by the Italian Society of Radiation Oncology
(AIRO). Tumori. 94:333–334. 2008.PubMed/NCBI
|
|
10
|
Frata P, Ponticelli P, Cosentino D,
Buffoli A, Di Pilla A, Morrica B and Palazzi M: Radiotherapy
resources for the care of head and neck patients in Italy. A survey
by the head and neck group of the Italian Association for Radiation
Oncology (AIRO). Tumori. 94:59–64. 2008.PubMed/NCBI
|
|
11
|
Caravatta L, Sallustio G, Pacelli F,
Padula GD, Deodato F, Macchia G, Massaccesi M, Picardi V, Cilla S,
Marinelli A, Cellini N, Valentini V and Morganti AG: Clinical
target volume delineation including elective nodal irradiation in
preoperative and definitive radiotherapy of pancreatic cancer.
Radiat Oncol. 7:862012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goodman KA, Regine WF, Dawson LA,
Ben-Josef E, Haustermans K, Bosch WR, Turian J and Abrams RA:
Radiation Therapy Oncology Group consensus panel guidelines for the
delineation of the clinical target volume in the postoperative
treatment of pancreatic head cancer. Int J Radiation Oncol Biol
Phys. 83:901–908. 2012. View Article : Google Scholar
|
|
13
|
Sainato A, Coppola M, Macchia G,
Bacigalupo A, Boz G, Sciacero P and Caravatta L: Pancreas -
Capitolo 3. La Radioterapia dei Tumori Gastrointestinali -
Indicazioni e Criteri Guida. Genovesi D, De Paoli A, Macchia G,
Sainato A, Lupattelli M, Osti MF, Friso ML, Gambacorta MA, Valvo F,
Mantello G, Niespolo R, Dionisi F and Genovesi D: referenti per
patologia. Associazione Italiana di Radioterapia Oncologica; pp.
69–118. 2012
|
|
14
|
AIRTUM working group: I numeri del cancro
in Italia 2012. Pancreas esocrino. 88–91. 2012.
|
|
15
|
Gillen S, Schuster T, Meyer Zum
Büschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant
therapy in pancreatic cancer: a systematic review and meta-analysis
of response and resection percentages. PLoS Med. 7:e10002672010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Colucci G, Di Costanzo F, Falconi M,
Trodella L, Reni M and Scarpa A: AIOM linee guida, carcinoma del
pancreas esocrino. 2013, http://www.aiom.ithttps://www.aiom.it. Last access
June 20, 2014.
|
|
17
|
Andriulli A, Festa V, Botteri E, Valvano
MR, Koch M, Bassi C, Maisonneuve P and Sebastiano PD:
Neoadjuvant/preoperative gemcitabine for patients with localized
pancreatic cancer: a meta-analysis of prospective studies. Ann Surg
Oncol. 19:1644–1662. 2012. View Article : Google Scholar
|
|
18
|
Heinemann V and Boeck S: Perioperative
management of pancreatic cancer. Ann Oncol. 19(Suppl 7):
vii273–vii278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ and
Büchler MW; European Study Group for Pancreatic Cancer: A
randomized trial of chemoradiotherapy and chemotherapy after
resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlk J, Zuelke C, Burkart C,
Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K,
Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken S
and Riess H: Adjuvant chemotherapy with gemcitabine vs observation
in patients undergoing curative-intent resection of pancreatic
cancer: a randomized controlled trial. JAMA. 297:267–277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neuhaus P, Riess H, Post S, Gellert K,
Ridwelski K, Schramm H, Zuelke C, Fahlke J, Langrehr J and Oettle
H: CONKO-001: final results of the randomized, prospective,
multicenter phase III trial of adjuvant chemotherapy with
gemcitabine vs. observation in patients with resected pancreatic
cancer (PC). J Clin Oncol. 26(Suppl): abs. LBA4504. 2008.
|
|
22
|
Neoptolemos JP, Stocken DD, Bassi C,
Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger
S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis
C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer
DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL and Büchler MW;
European Study Group for Pancreatic Cancer: Adjuvant chemotherapy
with fuorouracil plus folinic acid vs gemcitabine following
pancreatic cancer resection: a randomized controlled trial. JAMA.
304:1073–1081. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pancreatic Adenocarcinoma. v. 2: 2011,
National Comprehensive Cancer Network Practice Guidelines.
http://www.nccn.orghttps://www.nccn.org. Last access
June 20, 2014.
|
|
24
|
Hall WA, Colbert LE, Liu Y, Gillespie T,
Lipscomb J, Hardy C, Kooby DA, Prabhu RS, Kauh J and Landry JC: The
influence of adjuvant radiotherapy dose on overall survival in
patients with resected pancreatic adenocarcinoma. Cancer.
119:2350–2357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sohn TA, Yeo CJ, Cameron JL, Koniaris L,
Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH and Lillemoe
KD: Resected adenocarcinoma of the pancreas-616 patients: results,
outcomes, and prognostic indicators. J Gastrointest Surg.
4:567–579. 2000. View Article : Google Scholar
|
|
26
|
Yoshida T, Matsumoto T, Sasaki A, Shibata
K, Aramaki M and Kitano S: Outcome of paraaortic node-positive
pancreatic head and bile duct adenocarcinoma. Am J Surg.
187:736–740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brunner TB, Merkel S, Grabenbauer GG,
Meyer T, Baum U, Papadopoulos T, Sauer R and Hohenberger W:
Definition of elective lymphatic target volume in ductal carcinoma
of the pancreatic head based on histopathologic analysis. Int J
Radiat Oncol Biol Phys. 62:1021–1029. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kayahara M, Nagakawa T, Ueno K, Ohta T,
Takeda T and Miyazaki I: Lymphatic flow in carcinoma of the distal
bile duct based on a clinicopathologic study. Cancer. 72:2112–2117.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hishinuma S, Ogata Y, Tomikawa M, Ozawa I,
Hirabayashi K and Igarashi S: Patterns of recurrence after curative
resection of pancreatic cancer, based on autopsy findings. J
Gastrointest Surg. 10:511–518. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Crane CH, Abbruzzese JL, Evans DB, Wolff
RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters
PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q and
Janjan NA: Is the therapeutic index better with gemcitabine-based
chemoradiation than with 5-fluorouracil-based chemoradiation in
locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys.
52:1293–1302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang DT, Schellenberg D, Shen J, Kim J,
Goodman KA, Fisher GA, Ford JM, Desser T, Quon A and Koong AC:
Stereotactic radiotherapy for unresectable adenocarcinoma of the
pancreas. Cancer. 115:665–672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Koong AC, Christofferson E, Le QT, Goodman
KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J and Yang GP:
Phase II study to assess the efficacy of conventionally
fractionated radiotherapy followed by a stereotactic radiosurgery
boost in patients with locally advanced pancreatic cancer. Int J
Radiat Oncol Biol Phys. 63:320–323. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rwigema JC, Parikh SD, Heron DE, Howell M,
Zeh H, Moser AJ, Bahary N, Quinn A and Burton SA: Stereotactic body
radiotherapy in the treatment of advanced adenocarcinoma of the
pancreas. Am J Clin Oncol. 34:63–69. 2011. View Article : Google Scholar
|
|
34
|
Macchia G, Morganti AG, Cilla S, Ippolito
E, Massaccesi M, Picardi V, Mattiucci GC, Bonomo P, Tambaro R,
Pacelli F, Piermattei A, De Spirito M, Valentini V, Cellini N and
Deodato F: Quality of life and toxicity of stereotactic
radiotherapy in pancreatic tumours: a case series. Cancer Invest.
30:149–155. 2012. View Article : Google Scholar : PubMed/NCBI
|
